The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab

References

• RmaliKAPuntisMCJiangWGTumour-associated angiogenesis in human colorectal cancerColorectal Dis20079131417181841
   PubMed Web of Science ®Google Scholar
• TakahashiSVascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapyBiol Pharm Bull201134121785178822130231
   PubMed Web of Science ®Google Scholar
• ChekhoninVPSheinSAKorchaginaAAGurinaOIVEGF in tumor progression and targeted therapyCurr Cancer Drug Targets201313442344323167597
   PubMed Web of Science ®Google Scholar
• GeorgeMLTuttonMGJanssenFVEGF-A, VEGF-C, and VEGF-D in colorectal cancer progressionNeoplasia20013542042711687953
   PubMed Web of Science ®Google Scholar
• AndréTKotelevetsLVaillantJCVegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosaInt J Cancer200086217418110738243
   PubMed Web of Science ®Google Scholar
• TakahashiYKitadaiYBucanaCDClearyKREllisLMExpression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancerCancer Res19955518396439687664263
   PubMed Web of Science ®Google Scholar
• HaradaYOgataYShirouzuKExpression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancerInt J Clin Oncol20016522122811723743
   PubMedGoogle Scholar
• GarciaVGarciaJMSilvaJLevels of VEGF-A mRNA in plasma from patients with colorectal carcinoma as possible surrogate marker of angiogenesisJ Cancer Res Clin Oncol2008134111165117118461364
   PubMed Web of Science ®Google Scholar
• AoyagiYIinumaHHoriuchiAShimadaRWatanabeTAssociation of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6Oncol Lett20101225325922966290
   PubMed Web of Science ®Google Scholar
• GiatromanolakiAKoukourakisMISivridisEActivated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancerEur J Clin Invest2007371187888617883421
   PubMed Web of Science ®Google Scholar
• Al-MaghrabiJGomaaWBuhmeidaAQariYAl-QahtaniMAl-AhwalMPrognostic significance of VEGFR1/Flt-1 immunoexpression in colorectal carcinomaTumour Biol20143599045905124908415
   PubMedGoogle Scholar
• AbbasiOMashayekhiFMirzajaniEFakhriyeh AslSMahmoudiTSaeedi SaediHThe soluble VEGFR1 concentration in the serum of patients with colorectal cancerSurg Today201545221522024676933
   PubMed Web of Science ®Google Scholar
• DongGGuoXFuXPotentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancerCancer Sci2012103356156822182247
   PubMed Web of Science ®Google Scholar
• MartinsSFGarciaEALuzMAPardalFRodriguesMFilhoALClinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancerCancer Genomics Proteomics2013102556723603341
   PubMed Web of Science ®Google Scholar
• GrotheyAGalanisETargeting angiogenesis: progress with anti-VEGF treatment with large moleculesNat Rev Clin Oncol20096950751819636328
   PubMed Web of Science ®Google Scholar
• YeungYTebbuttNCBevacizumab in colorectal cancer: current and future directionsExpert Rev Anticancer Ther201212101263127323113577
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDíaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol200826122013201918421054
   PubMed Web of Science ®Google Scholar
• Van CutsemETaberneroJLakomyRAddition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimenJ Clin Oncol201230283499350622949147
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroARegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar
• BennounaJSastreJArnoldDML18147 Study InvestigatorsContinuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialLancet Oncol2013141293723168366
   PubMed Web of Science ®Google Scholar
• KubickaSGreilRAndréTML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER, GI, TTD, BGDO, GEMCAD, and AGMT groupsBevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findingsAnn Oncol20132492342234923852309
   PubMed Web of Science ®Google Scholar
• CunninghamDLangIMarcuelloEAVEX study investigatorsBevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialLancet Oncol201314111077108524028813
   PubMed Web of Science ®Google Scholar
• DouillardJYOlinerKSSienaSPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerN Engl J Med2013369111023103424024839
   PubMed Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol200826101626163418316791
   PubMed Web of Science ®Google Scholar
• Van CutsemEKöhneCHLángICetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusJ Clin Oncol201129152011201921502544
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• ReckMKaiserRMellemgaardALUME-Lung 1 Study GroupDocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol201415214315524411639
   PubMed Web of Science ®Google Scholar
• ZhangSMcCruddenCKwokHThe prognostic significance of combining VEGFa, FLT1 and KDR mRNA expressions in lung cancerOncol Lett2015in press
   Web of Science ®Google Scholar
• JorissenRNGibbsPChristieMMetastasis-associated gene expression changes predict poor outcomes in patients with Dukes Stage B and C colorectal cancerClin Cancer Res200915247642765119996206
   PubMed Web of Science ®Google Scholar
• SmithJJDeaneNGWuFExperimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancerGastroenterology2010138395896819914252
   PubMed Web of Science ®Google Scholar
• MarisaLde ReynièsADuvalAGene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic valuePLoS Med2013105e100145323700391
   PubMed Web of Science ®Google Scholar
• YuenHFGunasekharanVKChanKKRanGTPase: a candidate for Myc-mediated cancer progressionJ Natl Cancer Inst2013105747548823468463
   PubMedGoogle Scholar
• SorichMJWieseMDRowlandAKichenadasseGMcKinnonRAKarapetisCSExtended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trialsAnn Oncol2015261132125115304
   PubMed Web of Science ®Google Scholar
• SinicropeFAMahoneyMRSmyrkTCPrognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapyJ Clin Oncol201331293664367224019539
   PubMed Web of Science ®Google Scholar
• Pogue-GeileKYothersGTaniyamaYDefective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08J Natl Cancer Inst20131051398999223821759
   PubMedGoogle Scholar
• PriceTJHardinghamJELeeCKImpact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancerJ Clin Oncol201129192675268221646616
   PubMed Web of Science ®Google Scholar
• VenookANiedzwieckiDLenzHPhase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)Proc Am Soc Clin Oncol201432Suppl 15LBA3
   Web of Science ®Google Scholar
• PetrelliFCoinuABarniSFOLFIRI with cetuximab or bevacizumab: FIRE-3Lancet Oncol20141513e581e58225456373
   PubMed Web of Science ®Google Scholar
• HeinemannVvon WeikersthalLFDeckerTFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialLancet Oncol201415101065107525088940
   PubMed Web of Science ®Google Scholar
• InceWLJubbAMHoldenSNAssociation of k-ras, b-raf, and p53 status with the treatment effect of bevacizumabJ Natl Cancer Inst2005971398198915998951
   PubMedGoogle Scholar
• KaraODumanBBKaraBErdoganSParsakCKSakmanGAnalysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapyAsian Pac J Cancer Prev201213126397640123464465
   PubMedGoogle Scholar
• YangSXSteinbergSMNguyenDSwainSMp53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancerInt J Oncol20113851445145221399868
   PubMed Web of Science ®Google Scholar
• SaidRHongDSWarnekeCLP53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapyOncotarget20134570571423670029
   PubMedGoogle Scholar